Evidence map›Paper›PMID 24918730›Full record

ArticleJournal of biopharmaceutical statistics2015

Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control.

H-J Helms, N Benda, T Friede

Abstract read
In one paragraph

Article in Journal of biopharmaceutical statistics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

H-J Helmsa Department of Medical Statistics , University Medical Center Göttingen , Humboldtallee , Göttingen , Germany.
N Benda
T Friede

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a clinical dose finding study with active control a new drug with several dose levels is compared with an active comparator drug. The main focus of such studies often lies on the estimation of a target dose that leads to the same efficacy as the control. This article investigates the finite sample properties of the maximum likelihood estimation of the target dose and compares several approaches for constructing corresponding confidence intervals under the assumption of a linear dose-response curve and normal error terms. Furthermore, the impact of deviations from the model assumptions regarding the error distribution is explored.

Indexed as

Research DesignClinical Trials, Phase II as TopicConfidence IntervalsData Interpretation, StatisticalDose-Response Relationship, DrugDrug Dosage CalculationsHumansLikelihood FunctionsLinear ModelsPharmaceutical PreparationsTreatment OutcomePharmaceutical PreparationsActive controlDose-finding studyInverse regressionLinear model

Identifiers

PMID24918730
PMCPMC4566885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.